These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence? Jenkins M; Goldsmith D Curr Opin Cardiol; 2012 Jul; 27(4):429-40. PubMed ID: 22678410 [TBL] [Abstract][Full Text] [Related]
31. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE]. Zavidić T; Lodeta B; Lovrinić Đ Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of statins in patients with end-stage renal disease. Nemerovski CW; Lekura J; Cefaretti M; Mehta PT; Moore CL Ann Pharmacother; 2013 Oct; 47(10):1321-9. PubMed ID: 24259696 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
34. The lipid story in chronic kidney disease: a long story with a happy end? Kujawa-Szewieczek A; Więcek A; Piecha G Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316 [TBL] [Abstract][Full Text] [Related]
35. Lipid management in chronic kidney disease, hemodialysis, and transplantation. Montague T; Murphy B Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521 [TBL] [Abstract][Full Text] [Related]
36. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983 [TBL] [Abstract][Full Text] [Related]